로딩 중…
지수 로딩 중…
HK inno.N Corporation
195940· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩38,900+7.16%
2026-08-04
Financials
Valuation Metrics
HK inno.N Corporation's Market Cap is ₩1.1T. At end of 2025 it was ₩1.4T. Ranked #286 of 2,436 in KR market (top 12%), #74 of 1,649 on KOSDAQ (top 4%), #32 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 14%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.10T KRW | KR#286/2,436 Sec#32/234 |
| Revenue | 1.07T KRW | KR#381/2,436 Sec#12/234 |
| Net Income | 84.22B KRW | KR#246/2,436 Sec#15/234 |
| Total Assets | 2.07T KRW | KR#293/2,436 Sec#12/234 |
| Net Assets | 1.34T KRW | KR#229/2,436 Sec#11/234 |
| Employees | 1,721 | KR#160/2,436 Sec#8/234 |
| Value | ||
| P/E | 13.09x | KR#860/2,436 Sec#53/234 |
| P/B | 0.82x | KR#1,276/2,436 Sec#74/234 |
| PEG | 0.27x | KR#568/2,436 Sec#34/234 |
| P/S | 1.03x | KR#1,391/2,436 Sec#83/234 |
| EV/EBITDA | 12.84x | KR#742/2,436 Sec#41/234 |
| FCF Yield | 7.94% | KR#688/2,436 Sec#33/234 |
| Profitability | ||
| ROE | 6.30% | KR#868/2,436 Sec#67/234 |
| ROA | 4.07% | KR#779/2,436 Sec#67/234 |
| Op. Margin | 11.05% | KR#433/2,436 Sec#41/234 |
| Revenue Growth | 4.58% | KR#1,182/2,436 Sec#111/234 |
| Earnings Growth | 48.88% | KR#576/2,436 Sec#34/234 |
| Financial Health | ||
| Debt Ratio | 54.61% | KR#188/2,436 Sec#24/234 |
| Total Debt | 482.76B KRW | KR#304/2,436 Sec#11/234 |
| FCF | 87.49B KRW | KR#214/2,436 Sec#12/234 |
| Cash | 60.55B KRW | KR#661/2,436 Sec#33/234 |
| Current Ratio | 0.83x | KR#2,011/2,436 Sec#192/234 |
| Net Debt/EBITDA | 3.56x | KR#998/2,436 Sec#73/234 |
| Dividend | ||
| Div. Yield | 1.13% | KR#1,110/2,436 Sec#65/234 |
| Div. Growth | 17.14% | KR#468/2,436 Sec#26/234 |
| Performance | ||
| 1Y Return | -14.13% | KR#1,182/2,436 Sec#95/234 |
| 1M Return | -7.71% | KR#1,764/2,436 Sec#165/234 |
| From 52W High | -33.62% | KR#605/2,436 Sec#39/234 |
| 1Y MDD | -39.41% | KR#504/2,436 Sec#39/234 |
| Trading | ||
| Volume | 181,259 shares | KR#649/2,436 Sec#59/234 |
| Foreign Own. | 13.53% | KR#359/2,436 Sec#27/234 |
| Per Share | ||
| EPS | 2,973 KRW | KR#283/2,436 Sec#17/234 |
| BPS | 47,207 KRW | KR#250/2,436 Sec#18/234 |
Company Info
동사는 2014년 씨제이제일제당㈜의 제약사업부문 물적분할로 설립되어 2018년 한국콜마㈜에 인수됨. 전문의약품 제조판매업 등 ETC사업부문과 음료수 제조업 등 H&B사업부문으로 구분되며, 다양한 의약품과 원료의약품을 국내외 판매하고 있음. 신약 케이캡, 로바젯 등 핵심 제품을 보유하고 있으며, 암, 소화, 당뇨 같은 혁신적 파이프라인을 확보하며 발전시키고 있음. HK이노엔는 2014년에 설립되었으며 충청북도 청주시에 본사를 두고 있습니다.